Kavitha Ramchandran, MD
Kavitha Ramchandran MD is a Clinical Professor of Medicine in the Division of Oncology at Stanford University. She serves as the Associate Medical Director of Cancer Care Services for the Stanford Cancer Center, is the Associate Chief of Faculty Development for the Division of Oncology, and she is the Director of Clinician Educator Faculty Development for the Department of Medicine. She received her undergraduate degree in Human Biology from Stanford University, her MD degree and residency training at the University of California, San Francisco, and completed her fellowship in Medical Oncology and Palliative Medicine at Northwestern University, Chicago before joining the Stanford faculty in 2010. Dr. Ramchandran is recognized for her contributions as a leader in the research of thoracic malignancies with a specific focus in thymic epithelial tumors. She serves as a principal investigator and sub-investigator on several research trials that focus on developing novel approaches and identifying new targets for the treatment of both thoracic malignancies as well as rare tumors. Her research also focuses on developing care delivery models that incorporate values (patients, family members, and clinicians), as well as novel means of palliative care education. In addition, she is part of an active thoracic oncology trials group recruiting patients for clinical trials using novel therapeutics. She focuses on the integration of palliative and oncology care and is one of a small number of dual trained faculty who are working to build synergies between the fields of oncology and palliative medicine in the areas of supportive care research, and novel models of care.
Financial relationships
-
Attribution:SelfType of financial relationship:OtherIneligible company:Varian Medical Systems -Date added:01/11/2023Date updated:03/12/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:Curio ScienceDate added:01/11/2023Date updated:03/12/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:PathomiqDate added:01/11/2023Date updated:03/12/2024
-
Attribution:SelfType of financial relationship:OtherIneligible company:Group wellDate added:01/11/2023Date updated:03/12/2024